Wofür dieses Produkt bestimmt ist
OAA DUO exists to give practitioners a clearly delimited application field at the occipital transition, with a two-step texture sequence that supports consistent, reproducible routines.
Wo es angewendet wird
Die unten aufgeführten Zonen (Anwendungsbereich) sind die möglichen Anwendungsstellen. Das Produkt kann auf allen diesen Zonen oder gezielter auf einer oder mehreren davon angewendet werden, in Absprache mit Ihrer Behandlerin oder Ihrem Behandler.
Anwendungsbereich: head.
So wird es angewendet
- 01Cleanse and dry the four defined application zones.
- 02Bring 1 push (airless system) of phase 1 to the area indicated by your therapist or in the application zones specific for this product.
- 03Apply the product 2 times a day in this selected area, in a thin layer.
- 04Follow up by phase 2 of this product if indicated by your therapist, following the steps in the application sequence.
Anwendungsabfolge
Phase 1 · Week 1–2 · 1–2 applications per day
Neurodermal release
The first texture is applied thinly on the target zone within the possible application zones, in the official zone order: suboccipital, directly below the hairline; retroauricular, behind the ear; submandibular, from the angle of the mandible towards the chin; and pre-SCM, immediately anterior to the upper portion of the sternocleidomastoid. Zone order stays identical at every session.
Phase 2 · Week 3 evening · from week 4 morning and evening
Neurodermal integration
From week 3 phase 2 is added in the evening: phase 1 in the morning on the target zone, phase 2 in the evening on that same target zone. From week 4 — or once phase 1 is finished and phase 2 is also recommended by your therapist — phase 2 is applied on the target zone in the morning and in the evening until the product is finished.
Maintenance · 1–3 sessions per week
Continued routine
The sequence is continued at a reduced cadence. Frequency, zones and observations are recorded in the professional log sheet and reviewed at agreed intervals.
Was enthalten ist
Inhaltsstoffe werden mit Namen und Funktion angegeben. Mengenangaben der Zusammensetzung sind Teil der kontrollierten Herstellungsdokumentation und werden auf dieser Seite nicht veröffentlicht.
Aqua baseAqua
Sets the water phase that determines spreadability across a defined surface field.
GlycerinGlycerin
Keeps the applied layer supple so the same field can be worked repeatedly without dryness on the skin surface.
Shea butterButyrospermum parkii butter
Gives the texture enough body to stay on the applied zone rather than running along the hairline.
PanthenolPanthenol
Documented as a conditioning constituent of the cutaneous topical base; contributes to a smooth, non-tacky finish.
TocopherolTocopherol
Protects the lipid fraction over the shelf life of the record so successive batches stay comparable.
MSMDimethyl sulfone
Documented constituent of phase 1 and phase 2 of the OAA record; kept at a low level so the texture of both steps stays light and spreadable.
Rosemary leaf extractRosmarinus officinalis leaf extract
Gives phase 1 its recognisable aromatic signature, which practitioners use to distinguish the two textures during a session.
Magnesium chlorideMagnesium chloride
Documented constituent of the phase 2 water phase; contributes to the lighter, faster-absorbing texture of the integration step.
Sicherheit
- Nur zur äußerlichen kutanen topischen Anwendung auf intakter Haut.
- Kontakt mit Augen, Schleimhäuten und verletzter oder gereizter Haut vermeiden.
- Bei Reizungen die Anwendung beenden und Ihre Behandlerin oder Ihren Behandler konsultieren.
- Außerhalb der Reichweite von Kindern aufbewahren.
- Dies ist eine kutane topische Zusammensetzung. Es ist kein Arzneimittel und es wird keine therapeutische Aussage getroffen.
Aufbewahrung
Verschlossen und aufrecht lagern, vor direkter Sonneneinstrahlung und Hitze geschützt. Innerhalb des auf der Verpackung angegebenen Zeitraums verwenden.
Fragen
Is this a medicinal product?
No. SIRIAM formulations are cutaneous topical compositions. They are described by application region and composition, not directed at a therapeutic indication but rather at regulation of the nervous system. EMG validation will need to support this further in the future.
Who determines the application region?
The region is identified by a healthcare professional using anatomical landmarks and surface maps. Our documentation supports that conversation.
Can the formulation be combined with other routines?
Combination and sequencing are decided together with the treating professional. We document composition, application and response.
Dokumentenreferenz
- Produkt-ID
- SIR-OAA-01
- Familie
- DUO
- Version
- 2.1
- Charge
- OAA-2602
- Aktualisiert
- 2026-02
- Herausgegeben von
- SIRIAM LAB